Omeros and quantum leap announce first patients dosed with narsoplimab in the i-spy covid-19 trial

Seattle & san francisco--(business wire)--omeros corporation (nasdaq: omer) and quantum leap healthcare collaborative announced that dosing of patients with narsoplimab in the i-spy covid-19 trial began earlier this month. the i-spy covid-19 trial is an adaptive platform trial sponsored by quantum leap healthcare collaborative. the goal of the trial is to screen rapidly, in parallel, multiple promising agents in order to identify drugs that will have a high impact on reducing mortality and avoi
OMER Ratings Summary
OMER Quant Ranking